Reacts with HIV1.
Not yet tested in other species.
To produce this antibody the recombinant Rev (strain BRU) has been used as immunogen. The peptide sequences were not derived from particular strains of HIV1, but were designed as (artificial) B-clade (strain) consensus sequences. Sequences in Swiss prot belong to particular HIV1 strains.
For epitope mapping synthetic peptides were used.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500. Predicted molecular weight: 13 kDa.
Use at an assay dependent dilution.
RelevanceHIV1 expresses the trans-activator protein Rev which is required for virus growth as it promotes the localisation and expression of viral
RNA in the cytoplasm. Rev is a model experimental system for studying nuclear transport. The HIV1 Rev protein as viral protein is expressed early in the virus life cycle and thus may be important targets for the immune control of HIV1 infection.
Human immunodeficiency virus 1 Rev antibody
Protein Rev antibody
Regulator of expression of viral proteins antibody
Anti-HIV1 Rev antibody  images
Western blot - Anti-HIV1 Rev antibody  (ab25871)
Lane 1 : Anti-HIV1 Rev antibody  (ab25871) Lane 2 :
Lane 1 : Recombinant HIV1 Rev (B subtype) Lane 2 : Protein size marker
Predicted band size : 13 kDa
References for Anti-HIV1 Rev antibody  (ab25871)
This product has been referenced in:
Nomaguchi M et al. Natural single-nucleotide polymorphisms in the 3' region of the hiv-1 pol gene modulate viral replication ability. J Virol88:4145-60 (2014).
Read more (PubMed: 24478432) »